Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05700669

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

A Phase 1b/2 Basket Study to Assess the Safety and Efficacy of AsiDNA™ in Combination with Olaparib in Participants with Recurrent Solid Tumors

Sponsor: Valerio Therapeutics

Conditions Breast Cancer Metastatic Castration-resistant Prostate Cancer Recurrent Epithelial Ovarian Cancer

Interventions AsiDNA Olaparib

Updated 6 times since 2023 Last updated: Sep 12, 2024 Started: Feb 20, 2023 Primary completion: Oct 31, 2023 Completion: Oct 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Breast Cancer and Metastatic Castration-resistant Prostate Cancer and is currently completed. Valerio Therapeutics leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE1/PHASE2

Status: Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2023 — Apr 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valerio Therapeutics

Data source: Valerio Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States